High-dose fluconazole therapy for cryptococcal meningitis in patients with AIDS

Abstract

Fluconazole (800-1,000 mg iv) was administered to 14 consecutive patients with AIDS and cryptococcal meningitis. At 10 weeks the rate of clinical success was 54.5% (six of 11 patients responded to fluconazole); the Kaplan-Meier estimate of the response rate was 67.1%, and the overall mortality rate was 18.2% (two of 11 patients died). At the end of treatment, eight (72.7%) of 11 patients responded to fluconazole. The median time to the first negative cerebrospinal fluid (CSF) culture was 33.5 days (95% confidence interval, 18.3-67.3); the median time for patients with initial CSF cryptococcal antigen titers of ≤1:1,024 was 66 days compared with 18 days for patients with initial CSF cryptococcal antigen titers of <1:1,024 (P = .06). The median time to the first negative CSF culture for patients with an isolate for which the minimum inhibitory concentration (MIC) was 4 μg/mL was 56 days compared with 16 days for patients with an isolate for which the MIC was <4 μg/mL (P = .11). The mean serum and CSF levels of fluconazole at steady state were 42.47 ± 26.31 μg/mL and 36.63 ± 21.08 μg/mL, respectively (ratio of CSF:serum, 0.86). No treatment was interrupted and no dose was tapered because of side effects. High-dose fluconazole might be an effective and well-tolerated therapeutic option for patients with AIDS and acute cryptococcal meningitis.